Education
About Us
Working with TipRanks
Follow Us
Dermapharm Holding (DE:DMP)
:DMP
Total Valuation
Dermapharm Holding SE has a market cap or net worth of €1.84B. The enterprise value is €2.99B.
Market Cap€1.84B
Enterprise Value€2.99B
Share Statistics
Dermapharm Holding SE has 53,840,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding53,840,000
Owned by Insiders77.09%
Owned by Institutions―
Financial Efficiency
Dermapharm Holding SE’s return on equity (ROE) is 0.19 and return on invested capital (ROIC) is 7.65%.
Return on Equity (ROE)0.19
Return on Assets (ROA)0.05
Return on Invested Capital (ROIC)7.65%
Return on Capital Employed (ROCE)0.12
Revenue Per Employee327.08K
Profits Per Employee47.65K
Employee Count3,610
Asset Turnover0.57
Inventory Turnover1.22
Valuation Ratios
The current PE Ratio of Dermapharm Holding SE is 18.41. Dermapharm Holding SE’s PEG ratio is 0.47.
PE Ratio18.41
PS Ratio0.00
PB Ratio3.52
Price to Fair Value3.47
Price to FCF15.49
Price to Operating Cash Flow12.12
PEG Ratio0.47
Income Statement
In the last 12 months, Dermapharm Holding SE had revenue of 1.18B and earned 113.79M in profits. Earnings per share was 2.11.
Revenue1.18B
Gross Profit767.07M
Operating Income216.93M
Pretax Income172.00M
Net Income113.79M
EBITDA320.91M
Earnings Per Share (EPS)2.11
Cash Flow
In the last 12 months, operating cash flow was 175.69M and capital expenditures -38.24M, giving a free cash flow of 137.45M billion.
Operating Cash Flow175.69M
Free Cash Flow137.45M
Free Cash Flow per Share2.55
Dividends & Yields
Dermapharm Holding SE pays an annual dividend of €0.879, resulting in a dividend yield of 2.48%
Dividend Per Share€0.879
Dividend Yield2.48%
Payout Ratio45.78%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.51
52-Week Price Change-6.32%
50-Day Moving Average38.24
200-Day Moving Average36.56
Relative Strength Index (RSI)27.29
Average Volume (3m)25.36K
Important Dates
Dermapharm Holding SE upcoming earnings date is Aug 26, 2025, TBA Not Confirmed.
Last Earnings DateMay 15, 2025
Next Earnings DateAug 26, 2025
Ex-Dividend DateJun 27, 2025
Financial Position
Dermapharm Holding SE as a current ratio of 1.82, with Debt / Equity ratio of 162.07%
Current Ratio1.82
Quick Ratio0.78
Debt to Market Cap0.46
Net Debt to EBITDA2.67
Interest Coverage Ratio3.71
Taxes
In the past 12 months, Dermapharm Holding SE has paid 60.27M in taxes.
Income Tax60.27M
Effective Tax Rate0.35
Enterprise Valuation
Dermapharm Holding SE EV to EBITDA ratio is 9.20, with an EV/FCF ratio of 18.10.
EV to Sales2.50
EV to EBITDA9.20
EV to Free Cash Flow18.10
EV to Operating Cash Flow14.66
Balance Sheet
Dermapharm Holding SE has €121.71M in cash and marketable securities with €979.61M in debt, giving a net cash position of €857.91M billion.
Cash & Marketable Securities€121.71M
Total Debt€979.61M
Net Cash€857.91M
Net Cash Per Share€15.93
Tangible Book Value Per Share-€8.92
Margins
Gross margin is 49.15%, with operating margin of 18.37%, and net profit margin of 9.64%.
Gross Margin49.15%
Operating Margin18.37%
Pretax Margin14.57%
Net Profit Margin9.64%
EBITDA Margin27.18%
EBIT Margin19.51%
Analyst Forecast
The average price target for Dermapharm Holding SE is €46.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target€46.50
Price Target Upside36.36% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast4.00%
EPS Growth Forecast82.44%